Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 6/20 | 0.51 |
| ▸ | MAOB | P27338 | 5/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL988721 | 0.85 | MAOB (0.51) | APPMAOBSMN1; SMN2 | |
| SCHEMBL15595369 | 0.83 | APP (0.54) | APPMAOBNPC1RAB9ATDP1 | |
| SCHEMBL989460 | 0.82 | GRM5 (0.52) | APPMAOBSMN1; SMN2 | |
| SCHEMBL30339592 | 0.81 | ALOX5 (0.53) | MAOBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL190551 | 0.81 | ALOX5 (0.53) | MAOBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL18154590 | 0.81 | APP (0.51) | APPMAOBNPC1RAB9ATDP1 | |
| SCHEMBL16012226 | 0.81 | MAOB (0.54) | APPMAOBNPC1RAB9ATDP1 | |
| SCHEMBL31658841 | 0.81 | MAOB (0.54) | APPMAOBNPC1RAB9ATDP1 | |
| SCHEMBL29792641 | 0.80 | — | — | |
| SCHEMBL287199 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12370183-B2 | Compositions and methods for treating malaria | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2025-07-29 | — | — | US | disclosed |
| US-20230139910-A1 | COMPOSITIONS AND METHODS FOR TREATING MALARIA | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2023-05-04 | — | — | US | disclosed |
| US-20230139910-A1 | COMPOSITIONS AND METHODS FOR TREATING MALARIA | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2023-05-04 | — | — | US | disclosed |
| US-20230139910-A1 | COMPOSITIONS AND METHODS FOR TREATING MALARIA | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12370183-B2 | Compositions and methods for treating malaria | G6PD, QDPR, FASN | APP 1425/4885MAOB 355/4885NPC1 3037/4885 |
| US-20230139910-A1 | COMPOSITIONS AND METHODS FOR TREATING MALARIA | G6PD, QDPR, FASN | APP 1425/4885MAOB 355/4885NPC1 3037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.